

Rec'd PCT/PTO - 4 APR 2006

SLR:dm 04/04/06 5585-70293-01 508626 MON/P100681US

PATENT
Attorney Reference No. 5585-70293-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FILE COPY**In re application of:** Boden et al.**Application No.** 10/521,628**Filed:** September 8, 2005**Confirmation No.** 2023**For:** BETA SHEET TAPES RIBBONS IN TISSUE ENGINEERING**Examiner:** Not yet assigned**Art Unit:** 1712**Attorney Reference No.** 5585-70293-01**REQUEST FOR CORRECTED OFFICIAL FILING RECEIPT****TO:** Kathy Short

Fax No. 703-305-3230

PCT Help Desk—Filing Receipts

U.S. Patent and Trademark Office

(TOTAL PAGES TRANSMITTED: 15)

An error appears in the official Filing Receipt issued for the above-identified patent application, as follows:


The title of the application should be:

--BETA SHEET TAPES RIBBONS IN TISSUE ENGINEERING--

Attached hereto is a copy of the official Filing Receipt with the requested correction shown thereon. Also attached is a copy of the Preliminary Amendment that was submitted on January 13, 2005 with the first submission of items concerning a filing under 35 U.S.C. § 371. The title was amended in the Preliminary Amendment.

Please correct the identified error and issue a corrected official Filing Receipt.

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being facsimile transmitted to fax number 703-305-3230 on the date shown below.


Sheree Lynn Rybak, Ph.D.
Registration No. 47,913April 4, 2006
Date

cc: Docketing



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (C) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/521,628✓	09/08/2005 ✓	1712 ✓	1290	5585-70293-01 ✓	10 ✓	51 ✓	1 ✓

24197✓
 KLARQUIST SPARKMAN, LLP
 121 SW SALMON STREET
 SUITE 1600
 PORTLAND, OR 97204

PREVIOUSLY DOCKETED

CONFIRMATION NO. 2023✓

FILING RECEIPT



OC000000018321966

Date Mailed: 03/20/2006

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Neville Boden, Leeds, UNITED KINGDOM;✓
 Amalia Aggeli, Leeds, UNITED KINGDOM;✓
 Eileen Ingham, Leeds, UNITED KINGDOM;✓
 Jennifer Kirkham, Leeds, UNITED KINGDOM;✓

Power of Attorney: The patent practitioners associated with Customer Number 24197. ✓

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/GB03/03016 07/15/2003 ✓

Foreign Applications

UNITED KINGDOM 02162865 07/15/2002 ✓

Projected Publication Date: 06/29/2006 ✓

Non-Publication Request: No ✓

Early Publication Request: No ✓

** SMALL ENTITY ** ✓

Title

~~Networks~~ **BETA SHEET TAPES RIBBONS IN TISSUE ENGINEERING**

Preliminary Class

428

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process simplifies the filing of patent applications on the same invention in member countries, but does not result in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof

unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

WDN/SLR:dm 01/13/05 344434
PATENT

Express Mail No. EV514612960US
Date of Deposit: January 13, 2005
Attorney Reference Number 5585-70293-01
Application Number Currently Unknown

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Neville Boden, Amalia Agelli,
Eileen Ingham, and Jennifer Kirkham

Application No. Currently unknown

Filed: Herewith

Confirmation No. Currently unknown

For: BETA SHEET TAPES RIBBONS IN
TISSUE ENGINEERING

Examiner: Not yet assigned

Art Unit: Not yet assigned

Attorney Reference No. 5585-70293-01

MAIL STOP PCT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

PRELIMINARY AMENDMENT

Prior to examination of the above-identified patent application, please amend the application as follows to comply with national stage requirements.

Amendments to the Specification are on page 2.

Amendments to the Claims are reflected in the listing of claims, which begins on page 3.

Remarks are on page 11.

An Abstract is attached as a separate page at the end of this document.

WDN/SLR:dm 01/13/05 344434
PATENT

Express Mail No. EV514612960US
Date of Deposit: January 13, 2005
Attorney Reference Number 5585-70293-01
Application Number Currently Unknown

Amendments to the Specification

On page 1, line 1, please amend the title of the invention to read as follows:

~~--BETA SHEET TAPES RIBBONS IN TISSUE ENGINEERING NETWORKS--~~

On page 1, please insert the following paragraph beginning on line 3:

--This is the U.S. National Stage of International Application No. PCT/GB2003/003016, filed July 15, 2003 (published in English under PCT Article 21(2)), which in turn claims the benefit of Great Britain patent application no. 0216286.5 filed July 15, 2002.--

Please insert the Abstract, submitted herewith on a separate page, as page 42 at the end of the application.

WDN/SLR:dm 01/13/05 344434
PATENT

Express Mail No. EV514612960US
Date of Deposit: January 13, 2005
Attorney Reference Number 5585-70293-01
Application Number Currently Unknown

Claims

1. (currently amended) A material comprising ribbons, fibrils or fibres, wherein characterised in that each of the ribbons, fibrils or fibres have an antiparallel arrangement of peptides in a β - sheet tape-like substructure.
2. (currently amended) A The material according to claim 1, wherein characterised in that the peptide is selected from the group P11-1, P11-2, P11-3, P11-4, P11-5, P11-6 and or P10-7.
3. (currently amended) A The material according to claim 1, wherein characterised in that the material comprises a self assembling peptide (SAP), wherein the SAP forms a tape in an aqueous medium and is made up of 3 or more polar/neutral amino acids and a plurality of charged amino acids.
4. (currently amended) A The material according to claim 3, wherein characterised in that the ratio of polar/neutral amino acids to charged amino acids is from 11:1 to 11:3.
5. (currently amended) A The material according to claim 3, wherein characterised in that the polar/neutral amino acids, which may be the same or different, and are selected from the group including comprise glutamine, serine, asparagine, glutamic acid, ornithine, cysteine, lysine, histidine and or threonine.
6. (currently amended) A The material according to claim 3, wherein characterised in that the amino acids are positively charged and form a gel at a pH of less than or equal to a neutral pH.
7. (currently amended) A The material according to claim 3, wherein characterised in that the amino acids are negatively charged and form a gel at a pH of greater than or equal to a neutral pH.

WDN/SLR:dm 01/13/05 344434
PATENT

Address Mail No. EV514612960US
Date of Deposit: January 13, 2005
Attorney Reference Number 5585-70293-01
Application Number Currently Unknown

8. (currently amended) A The material according to claim 3, wherein characterised in that the SAP is P11-1.

9. (currently amended) A The material according to claim 3, wherein characterised in that the amino acid chain is extended to include a bioactive peptide sequence.

10. (currently amended) A The material according to claim 3, wherein characterised in that the amino acid chain is attached to a therapeutically active molecule.

11. (currently amended) A The material according to claim 1, wherein characterised in that the material comprises an SAP which forms ribbons and/or fibrils in an aqueous solution and wherein the SAP has a primary structure in which at least 50% of the amino acids comprise an alternating structure of polar and apolar amino acids.

12. (currently amended) A The material according to claim 11, wherein characterised in that the polar amino acids include from 1 to 3 net charged amino acids per 11 amino acids.

13. (currently amended) A The material according to claim 12, wherein characterised in that the SAP is selected from the group P11-2, P11-3, P11-4 and or P11-5.

14. – 16. (canceled)

17. (currently amended) A The material according to claim 11, wherein characterised in that the material comprises a self assembling peptide (SAP) wherein the SAP forms a tape in an aqueous medium and is made up of 3 or more polar/neutral amino acids and a plurality of charged amino acids.

18. (canceled)

WDN/SLR:dm 01/13/05 344434
PATENT

Business Mail No. EV514612960US
Date of Deposit: January 13, 2005
Attorney Reference Number 5585-70293-01
Application Number Currently Unknown

19. (currently amended) A The material according to claim 11, wherein characterised in that the apolar amino acids, ~~which may be the same or different, and are selected from the group including~~ comprise phenylalanine, tryptophan, valine, leucine, isoleucine and or methionine.

20. (currently amended) A The material according to claim 17, wherein characterised in that the amino acid chain is extended to include a bioactive peptide sequence.

21. (currently amended) A The material according to claim 17, wherein ~~18~~ characterised in that the amino acid chain is attached to a therapeutically active molecule.

22. (canceled)

23. (currently amended) A The material according to claim 11, wherein characterised in that the SAP is soluble in a highly ionic medium.

24. (currently amended) A The material according to claim 23, wherein characterised in that the SAP comprises a ratio of net charged amino acids to total amino acids of from 1:11 to 4:11.

25. – 27. (canceled)

28. (currently amended) A The material according to claim 3, wherein characterised in that the tapes are alternating peptide or complementary peptide tapes.

29. (currently amended) A The material according to claim 28, wherein characterised in that the complementary peptide tapes are made up of 3 or more polar amino acids of which some are charged amino acids wherein the ratio of charged amino acids to total amino acids is 3:11 or greater.

30. – 35. (canceled)

WDN/SLR:dm 01/13/05 344434
PATENT

Express Mail No. EV514612960US
Date of Deposit: January 13, 2005
Attorney Reference Number 5585-70293-01
Application Number Currently Unknown

36. (currently amended) A The material according to claim 1, wherein characterised in that the persistence length of the ribbons, fibrils or fibres is from 20 nm - 70 μ m.

37. (currently amended) A The material according to claim 36, wherein characterised in that the peptide is a P11-3 variant.

38. (currently amended) A The material according to claim 1, wherein characterised in that the material substantially comprises ribbons, fibrils, or fibres.

39. - 40. (cancelled)

41. (currently amended) A The material according to claim 38, wherein the material substantially comprises fibrils, and wherein 39 characterised in that the fibrils are comprised in a network of fibrils interconnected at fibre-like junctions.

42. (currently amended) A The material according to claim 1, wherein characterised in that a solution of the material has a nematic transition occurring at $C_{IN} = 0.9$ mM.

43. (currently amended) A The material according to claim 38, wherein claims 39 or 40 characterised in that the fibrils or fibres are in the form of a nematic fluid.

44. (currently amended) A The material according to claim 43, wherein characterised in that the nematic fluid is an elastomeric gel.

45. (currently amended) A The material according to claim 1, wherein characterised in that the material is in the form of a tissue engineering scaffold.

46. (currently amended) A The material according to claim 45, wherein characterised in that the scaffold is seeded with cells.

WDN/SLR:dm 01/13/05 344434
PATENT

Express Mail No. EV514612960US
Date of Deposit: January 13, 2005
Attorney Reference Number 5585-70293-01
Application Number Currently Unknown

47. (currently amended) A The material according to claim 47, wherein characterised in that the cells may be are ligamentum cells for growing new ligaments, tenocytes for growing new tendon, chondrocytes for cartilage, osteoblasts for bone, cardiac cells for cardiac tissue engineering, stromal cells for tissue patches, fibroblasts and keratinocytes for skin and mesenchymal stem cells for any of these applications.

48. (currently amended) A The material according to claim 1, wherein characterised in that the material possess one or more of the features selected from high tensile strength at low weight, high modulus, high chemical resistance, high toughness, high cut resistance, low elongation to break, low thermal shrinkage, high dimensional stability, and flame resistant, or and self extinguishing.

49. (currently amended) A The material according to claim 1, wherein characterised in that the processed fibres possess characteristics selected from the following: continuous filament yarn, high tensile strength, processable on conventional looms, twisters, cord forming, stranding and serving equipment; staple, very high cut resistance, spun on conventional cotton or worsted spinning equipment, precision cut short fibres, processable on felting and spun lace equipment; pulp-wet and dry, floc, precision cut short fibres, high surface area, miscible in blend composites, thermal resistance, excellent friction and wear resistance; cord, high tensile strength and modulus at low specific weight, retention of physical properties at high and low temperature extremes, very low heat shrinkage, very low creep, good fatigue resistance; fabric, excellent ballistic performance at low weights; and excellent resistance to cuts and protrusion combined with comfortable wear and excellent friction and wear performance against other materials.

50. (currently amended) A The material according to claim 1, wherein characterised in that the material comprises a skin treatment.

51. (currently amended) A The material according to claim 50, wherein characterised in that the skin treatment comprises skincare and dermatological applications for cosmetic and/or medical treatment.

WDN/SLR:dm 01/13/05 344434
PATENT

Express Mail No. EV514612960US
Date of Deposit: January 13, 2005
Attorney Reference Number 5585-70293-01
Application Number Currently Unknown

52. (currently amended) A The material according to claim 50, wherein characterised in that the skin treatment comprises one or more of skin protection, improvement in skin feel, improvement of skin strength, increased suppleness, delivery of active or beneficial substances, moisturisation, improved appearance and/or anti-ageing effects.

53. (currently amended) A The material according to claim 1, wherein characterised in that the material comprises a hair care product.

54. (currently amended) A The material according to claim 53, wherein characterised in that the ~~that~~ the hair care product ~~comprises a hair care to improve~~ s hair condition, strength, feel, suppleness, appearance and/or moisturisation.

55. (currently amended) A The material according to claim 54, wherein characterised in that the ~~that~~ the hair care product comprises a hair shampoo, conditioner, dye, gel, mousse and/or other dressing.

56. (currently amended) A The material according to claim 1, wherein characterised in that the material comprises a network adapted for the delivery of perfumes, vitamins and/or other beneficial agents to the skin and/ or hair.

57. (currently amended) A The material according to claim 56, wherein characterised in that pH responsiveness is used to control the delivery process.

58. (currently amended) A The material according to claim 1, wherein characterised in that the material is sterilised.

59. -- 60. (canceled)

WDN/SLR:dm 01/13/05 344434
PATENT

Express Mail No. EV514612960US
Date of Deposit: January 13, 2005
Attorney Reference Number 5585-70293-01
Application Number Currently Unknown

61. (currently amended) A method of tissue engineering, comprising seeding the material of claim 1 with cells which comprises the use of a SAP as a scaffold.
62. (canceled)
63. (currently amended) A The method of tissue engineering according to claim 61, wherein the method is a method of which comprises bone repair.
64. – 68. (canceled)
69. (currently amended) A method of sterilising a the material according to claim 1, comprising which comprises gamma irradiation of a dry powder of the material.
70. (canceled)
71. (currently amended) The use of a material according to claim 1, wherein the material can modify in the modification of the wetting properties or anti-icing properties of a material, for controlling the control interaction of oil/water with clay surfaces, the stabilising of stabilize clay itself or dealing with fractures in oil-wells.
72. (currently amended) The use of a material according to claim 1, wherein the material is part of a sensor, biocatalyst or in the manufacture of materials for use as sensors, as biocatalysts, or as separation media in biotechnology applications.
73. (currently amended) The use of a material according to claim 1, wherein the material is part of a in the manufacture of bioresponsive and biocompatible surfaces produced by adhesion, spreading and growth of endothelial cells in medical implant materials.
74. – 75. (canceled)

WDN/SLR:dm 01/13/05 344434
PATENT

Express Mail No. EV514612960US
Date of Deposit: January 13, 2005
Attorney Reference Number 5585-70293-01
Application Number Currently Unknown

76. (currently amended) The ~~use of a material according to claim 1, wherein the material can serve as a template for the nucleation and growth of inorganic materials.~~

77. - 80. (canceled)

81. (currently amended) The ~~use of a material according to claim 1, wherein the material comprises in the manufacture of a material selected from one or more of the following forms; continuous filament yarns, staple, floc, cord, or and fabric.~~

82. – 95. (canceled)

96. (currently amended) A scaffold constructed using a combination of ~~The material according to claim 1, further comprising a polymer and other existing commercial and/or naturally occurring polymers.~~

97. - 99. (canceled)

WDN/SLR:dm 01/13/05 344434
PATENT

Express Mail No. EV514612960US
Date of Deposit: January 13, 2005
Attorney Reference Number 5585-70293-01
Application Number Currently Unknown

Remarks

Claims 1-99 were pending. By this amendment, claims 14-16, 18, 22, 25-27, 30-35, 39-40, 59-60, 62, 64-68, 70, 74-75, 77-80, 82-95, and 97-99 are cancelled without prejudice to prosecution in another application. No claims were added. Therefore, claims 1-13, 17, 19-21, 23-24, 28-29, 36-38, 41-58, 61, 63, 69, 71-73, 76, 81, and 96 are now pending.

Claims were amended to comply with United States claiming practice, for example to correct antecedent basis and to amend use claims. Support for the amendment to claim 61 can be found throughout the application, for example page 15, line 16 – page 16, line 20.

By this amendment the specification has been updated to reflect prior related applications and to insert the abstract on a separate page, and the title of the invention has been amended.

No new matter has been added by this amendment.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By 
Sheree Lynn Rybak, Ph.D.
Registration No. 47,913

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446